|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9241948||SUN PHARM||Ready to be infused gemcetabine solution|| |
(9 years from now)
Infugem is owned by Sun Pharm.
Infugem contains Gemcitabine Hydrochloride.
Infugem has a total of 1 drug patent out of which 0 drug patents have expired.
Infugem was authorised for market use on 16 July, 2018.
Infugem is available in solution;intravenous dosage forms.
The generics of Infugem are possible to be released after 01 July, 2033.
Market Authorisation Date: 16 July, 2018
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic